Drug Trial Radar · NCT07342803
Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients
Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jan 25, 2025
Primary completion
Dec 28, 2027
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Longbio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jan 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, masked, active and placebo controlled, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-003 injection in adult patients with moderate to severe persistent allergic asthma.
Conditions
- Allergic Asthma
Interventions
LP-003 InjectionBiological
s.c. injection, Q12W
OmalizumabBiological
s.c. injection, Q4W
PlaceboBiological
s.c. injection, Q4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean number of asthma exacerbations per subjectTime frame: During the 24-week treatment period
- Proportion of subjects with asthma exacerbationsTime frame: During the 24-week treatment period
- Mean number of asthma exacerbations per subjectTime frame: During the 36-week and 48-week follow-up period
- Proportion of subjects with asthma exacerbationsTime frame: During the 36-week and 48-week follow-up period
- Proportion of subjects with loss of asthma control (LOAC) in each groupTime frame: During the 24-week treatment period
- Incidence of adverse events (AEs)Time frame: Up to approximately 52 weeks
- Change from baseline in pre-bronchodilator FEV1, FVC, and FEV1/FVC ratioTime frame: Weeks 4, 8, 12, 16, 20, and 24
- Change from baseline in weekly mean daily and weekly Peak Expiratory Flow (PEF) variability, and change from baseline in mean PEFTime frame: Weeks 4, 8, 12, 16, 20, and 24
- Time to first asthma exacerbation from baselineTime frame: Up to approximately 52 weeks
- Change from baseline in weekly use of reliever medication (Salbutamol Sulfate Aerosol)Time frame: Up to approximately 52 weeks
- Change from baseline in weekly Asthma Symptom Diary ScoreTime frame: Up to approximately 52 weeks
- Change from baseline in standardized Asthma Quality of Life Questionnaire (AQLQ(S))Time frame: Weeks 12 and 24
- Change from baseline in Asthma Control Questionnaire (ACQ-5)Time frame: Weeks 12 and 24
- Change from baseline in Asthma Control Test (ACT)Time frame: Weeks 12 and 24
- Change in serum free IgE levels over time at different time pointsTime frame: Up to approximately 52 weeks
- Serum concentrations of LP-003 at different time pointsTime frame: Up to approximately 52 weeks
- Incidence of Anti-drug Antibodies (ADA)Time frame: Up to approximately 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.